Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00315_DB01037_nanopub.RA9XZ226CcIYkwhtZnYJ4ziPoXHeFiD9NbvBH7hbvFT1s#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00315_DB01037 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00315_DB01037 label "DDI between Zolmitriptan and Selegiline - The MAO inhibitor, selegiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing selegiline are contraindicated. [drugbank_resource:DB00315_DB01037]" assertion.
- drugbank_resource:DB00315_DB01037 identifier "drugbank_resource:DB00315_DB01037" assertion.
- drugbank_resource:DB00315_DB01037 title "DDI between Zolmitriptan and Selegiline - The MAO inhibitor, selegiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing selegiline are contraindicated." assertion.
- drugbank:DB01037 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00315_DB01037 assertion.
- drugbank:DB00315 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00315_DB01037 assertion.